30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

Anika Therapeutics Company Profile

Of Anika's broadening portfolio of orthobiologic products, ORTHOVISC sits at #1 in the U.S. multi-injection viscosupplement segment, and MONOVISC at #2 in single-injection. The company ended 2016 with orthobiologic revenues of $89.7MM, +22.5% vs. 2015.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.